Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 23Head and Neck Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Squamous Cell 8Neoplasms 7Lung Neoplasms 7Colonic Neoplasms 7Rectal Neoplasms 6Esophageal Neoplasms 5Carcinoma 5Recurrence 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Neoplasms, Squamous Cell 3Hereditary Sensory and Autonomic Neuropathies 3Glioblastoma 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Cancer Metastatic 3Breast Neoplasms 3Tongue Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Melanoma 2Glioma 2

Interventions

durvalumab 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Appendiceal Neoplasms × Cetuximab × Clear all
NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
48 enrolled
Gastrointestinal

Appendiceal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡